FDA reverses course, decides not to add suffixes to older biologics’ nonproprietary names
The FDA has decided not to go back and rename biologics’ nonproprietary names with nonsense suffixes, as it once said it would, raising questions about …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
